Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

131
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
131
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Therapies02:49

Cancer Therapies

10.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zipalertinib-A Novel Treatment Opportunity for Non-Small Cell Lung Cancers with Exon 20 Insertions and Uncommon EGFR Mutations.

Cancers·2026
Same author

Real-world efficacy of atezolizumab combined with etoposide and platinum chemotherapy in extensive-stage small cell lung cancer: a retrospective cohort study.

Journal of thoracic disease·2025
Same author

Prognostic roles of hematological indicators in programmed cell death protein 1/programmed cell death ligand 1 inhibitors for small-cell lung cancer: a retrospective cohort study.

Journal of thoracic disease·2025
Same author

TET2 cascade: a novel regulator of chromatin structure and leukaemogenesis.

Signal transduction and targeted therapy·2025
Same author

Targeting C797S mutations and beyond in non-small cell lung cancer-a mini-review.

Translational cancer research·2024
Same author

Somatic <i>KMT2D</i> loss-of-function mutations in lung squamous cell carcinoma: a single-center cohort study.

Journal of thoracic disease·2024

Related Experiment Video

Updated: Apr 12, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

543

Targeted Therapy for NSCLC--A Double-edged Sword?

Wolfram C M Dempke1

  • 1University Hospital of Grosshadern (LMU Munich, Haematology and Oncology), Munich, Germany wolfram.dempke@astrazeneca.com.

Anticancer Research
|May 13, 2015
PubMed
Summary
This summary is machine-generated.

Targeted therapies like EGFR tyrosine kinase inhibitors improve progression-free survival in non-small cell lung cancer (NSCLC) but often fail to improve overall survival due to resistance. New predictive markers are needed for better treatment decisions.

Keywords:
NSCLCclinical trialsmonoclonal antibodiesnovel therapiesreviewtyrosine kinase inhibitors

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.6K

Related Experiment Videos

Last Updated: Apr 12, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

543
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.6K

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Advanced non-small cell lung cancer (NSCLC) has a poor prognosis with limited treatment options.
  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show efficacy in patients with activating EGFR mutations, improving progression-free survival (PFS).
  • Resistance to TKIs is common, and overall survival (OS) benefits are not consistently observed, highlighting a need for improved therapeutic strategies.

Purpose of the Study:

  • To review the current landscape of targeted therapies in advanced NSCLC.
  • To discuss the challenges and limitations of existing treatments, particularly regarding resistance and overall survival.
  • To emphasize the need for better predictive markers and a deeper understanding of resistance mechanisms.

Main Methods:

  • Review of existing literature on targeted therapies in NSCLC, including EGFR inhibitors and other agents like bevacizumab and crizotinib.
  • Analysis of clinical trial data focusing on progression-free survival (PFS) and overall survival (OS) as key outcomes.
  • Discussion of emerging therapeutic strategies targeting angiogenesis and other signaling pathways.

Main Results:

  • First-generation EGFR TKIs improve PFS in NSCLC patients with EGFR mutations, but OS benefits are limited, and resistance frequently develops.
  • While several new agents targeting EGFR pathways and angiogenesis are in development, many have only shown improved PFS without significant OS gains.
  • Current evidence does not support unselected addition of TKIs to chemotherapy due to limited demonstrated benefit.

Conclusions:

  • There is a critical need to understand the complex mechanisms of TKI resistance in NSCLC.
  • Development of validated predictive markers is essential for personalized treatment selection and avoiding ineffective therapies.
  • Further research into resistance mechanisms will facilitate the discovery of novel targets and more effective drugs for NSCLC treatment.